Agreement with BARDA aims to accelerate development.
Allucent, a clinical research organization (CRO), has officially been chosen to fast-track clinical research and development for new COVID-19 vaccine candidates by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. As part of the contract, Allucent will hold a 10,000-participant Phase IIb clinical trial designed to measure efficacy of next-generation vaccine candidates compared to authorized treatments to prevent symptomatic, PCR-confirmed SARS-CoV-2 infection.
"Allucent is honored to have been chosen by BARDA for this critical initiative," said Mark A. Goldberg, MD, chairman, CEO, Allucent, in a company press release. "This collaboration represents a significant step forward in our collective efforts to combat COVID-19 and its variants. We are excited to leverage our expertise and resources to help develop next-generation booster vaccines that will enhance global immunity and save lives. This award results from our focused investment in countering infectious diseases and further builds upon our growing federally funded clinical trials portfolio."
Reference: Allucent Awarded BARDA Contract to Support Acceleration of Next-Generation COVID-19 Booster Vaccines. PR Newswire. August 28, 2023. Accessed August 29, 2023. https://www.prnewswire.com/news-releases/allucent-awarded-barda-contract-to-support-acceleration-of-next-generation-covid-19-booster-vaccines-301910678.html
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.